Stock Events

Stock Events

Helix Biopharma 

€0.82
12
-€0.04-4.65% Thursday 06:06

Statistics

Day High
0.82
Day Low
0.82
52W High
3.56
52W Low
0.43
Volume
-
Avg. Volume
-
Mkt Cap
148.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17JunExpected
Q3 2024
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q4 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-6.67MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HBP0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech firm developing innovative therapeutics, including in oncology, which competes with Helix's cancer-focused treatments.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences focuses on antiviral drugs and cancer therapies, directly competing with Helix's research in cancer treatment.
Merck
MRK
Mkt Cap298.84B
Merck is a global healthcare company that develops cancer drugs and vaccines, overlapping with Helix's oncology focus.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb offers a wide range of cancer treatments, competing in the same therapeutic areas as Helix.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops and manufactures drugs and vaccines, including for cancer, making it a competitor in Helix's market.
Novartis
NVS
Mkt Cap297.32B
Novartis is a healthcare company with a strong emphasis on research and development in oncology, competing with Helix's cancer therapies.
Roche
RHHBY
Mkt Cap321.08B
Roche operates in the pharmaceutical and diagnostics sectors, with a significant focus on oncology, directly competing with Helix.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca specializes in the discovery, development, and commercialization of prescription medicines, including for cancer, competing with Helix.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is known for its innovative biopharmaceuticals, competing in the oncology space with Helix.

About

Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Show more...
CEO
ISIN
CA4229102088
WKN
000A40GN1

Listings

TO
CA
HBP.TO
F
DE
HBP0.F
OTC Link
US
HBPCF

0 Comments

Share your thoughts

FAQ

What is Helix Biopharma stock price today?▼
The current price of HBP0.F is €0.82 EUR — it has decreased by -4.65% in the past 24 hours. Watch Helix Biopharma stock price performance more closely on the chart.
What is Helix Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Helix Biopharma stocks are traded under the ticker HBP0.F.
Is Helix Biopharma stock price growing?▼
HBP0.F stock has fallen by -10.38% compared to the previous week, the month change is a -17.17% fall, over the last year Helix Biopharma has showed a +83.04% increase.
What is Helix Biopharma market cap?▼
Today Helix Biopharma has the market capitalization of 148.24M
When is the next Helix Biopharma earnings date?▼
Helix Biopharma is going to release the next earnings report on June 17, 2026.
What is Helix Biopharma revenue for the last year?▼
Helix Biopharma revenue for the last year amounts to 0 EUR.
What is Helix Biopharma net income for the last year?▼
HBP0.F net income for the last year is -6.67M EUR.
When did Helix Biopharma complete a stock split?▼
Helix Biopharma has not had any recent stock splits.